WallStreetZenWallStreetZen

NYSEMKT: LCTX
Lineage Cell Therapeutics Inc Stock Ownership - Who owns Lineage Cell Therapeutics?

OverviewForecastEarningsDividendOwnership

Insider buying vs selling

Have Lineage Cell Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Brian M. CulleyPresident and CEO2024-02-1112,806$1.08
$13.83kSell
George A. Samuel IiiGeneral CounselSecretary2024-02-112,490$1.08
$2.69kSell
Don M. BaileyDirector2024-02-0896,155$1.04
$100.00kBuy
Broadwood Partners LPDirector2024-02-066,730,770$1.04
$7.00MBuy
Anula JayasuriyaDirector2023-12-2910,000$1.09
$10.90kBuy

1 of 1

LCTX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when LCTX insiders and whales buy or sell their stock.

LCTX Shareholders

What type of owners hold Lineage Cell Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Broadwood Partners LP39.06%73,636,522$81.74MInsider
Neal C. Bradsher25.20%47,515,269$52.74MInsider
Broadwood Capital Inc18.53%34,935,485$38.78MInstitution
Alfred D. Kingsley5.49%10,344,637$11.48MInsider
Blackrock Inc4.53%8,531,498$9.47MInstitution
Vanguard Group Inc4.45%8,384,687$9.31MInstitution
George Karfunkel2.64%4,982,217$5.53MInsider
Defender Capital LLC2.64%4,969,675$5.52MInstitution
Geode Capital Management LLC1.56%2,935,811$3.26MInstitution
Gary K. Duberstein1.37%2,590,408$2.88MInsider

1 of 3

LCTX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
LCTX34.36%65.64%Net BuyingNet Buying
MACK23.49%76.51%Net Buying
GALT8.36%91.64%Net BuyingNet Selling
STRO78.85%21.15%Net SellingNet Selling
DSGN42.98%57.02%Net BuyingNet Buying
View Top Biotech Stocks

Lineage Cell Therapeutics Stock Ownership FAQ

Who owns Lineage Cell Therapeutics?

Lineage Cell Therapeutics (NYSEMKT: LCTX) is owned by 40.16% institutional shareholders, 76.71% Lineage Cell Therapeutics insiders, and 0.00% retail investors. Broadwood Partners LP is the largest individual Lineage Cell Therapeutics shareholder, owning 73.64M shares representing 39.06% of the company. Broadwood Partners LP's Lineage Cell Therapeutics shares are currently valued at $83.95M.

If you're new to stock investing, here's how to buy Lineage Cell Therapeutics stock.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.